Regulation of Research into Biological Disease Agents Law, 5769-2008
חוק הסדרת מחקרים במחוללי מחלות ביולוגיים, תשס"ט-2008
Unofficial English translation — for reference only. It may contain errors or omissions and cannot be relied on as a legal text. Only the Hebrew text published in Reshumot is legally binding.More
This English text was translated from the official Hebrew using a range of translation tools, and it undergoes ongoing checks and updates. It is not a certified translation.
Despite these checks, it may contain errors, omissions, or imprecise renderings of legal terminology and cross-references, and it may not yet reflect the latest amendments. It cannot be relied upon as a legal text.
The Hebrew text as published in Reshumot (ספר החוקים) and on the Knesset website is the sole authoritative and legally binding version. In any discrepancy, the Hebrew text prevails.
This translation is provided for informational purposes only and does not constitute legal advice. For use in legal proceedings, request a certified Expert Legal Opinion.
Chapter V: Supervision
Authorisation of Inspectors§
The Director may authorise, from among the employees of his Ministry, an inspector with powers under this Law, provided that all of the following conditions are satisfied in respect of him:
Supervision§
For the purpose of supervising the implementation of the provisions under this Law, an inspector may:
Right to be Heard§
Notwithstanding the provisions of section 19, an inspector shall not give a direction as referred to therein to seize or destroy disease agents or other materials except after having given the institution or the researcher, as the case may be, an opportunity to present their arguments; however, if the inspector finds that delaying the giving of the direction is liable to endanger state security or public safety, health or welfare, he may give it immediately, provided that he gives the institution or the researcher, as the case may be, the opportunity to present their arguments at the earliest opportunity thereafter.
Chapter VI: Penalties
Penalties§
Liability of an Office Holder in a Corporation§
Chapter VII: General Provisions
Maintenance of Confidentiality§
A person performing a function by virtue of this Law shall not disclose any information or the contents of any document that came to his knowledge by virtue of his function, except in accordance with law.
Amendment of the Schedule§
The Minister shall amend the Schedule from time to time, with the approval of the Science and Technology Committee of the Knesset.
Implementation and Regulations§
The Minister is responsible for the implementation of this Law, and shall prescribe provisions in all matters relating to its implementation, including with respect to the manner of submitting applications for research and the granting of approvals, and after consultation with the Minister of Defence – with respect to conditions for the recognition of an institution and methods of supervision and control.
Limitation on Application to the Security Establishment§
The provisions of this Law shall not apply to the security establishment; however, the possession of disease agents and the conduct of research therein shall be carried out in accordance with guidelines to be issued –
Commencement and Transitional Provision§
Schedule (Section 1)
The definition "disease agents"
Abrin;
Bacillus anthracis;
Botulinum neurotoxins;
Botulinum neurotoxin producing species of Clostridium;
Brucella abortus;
Brucella melitenis;
Brucella suis;
Burkolderia mallei (glanders);
Burkholderia pseudomallei (melioidosis);
Camel pox virus;
Central European Tick-borne encephalitis;
Ceropithecine herpesvirus 1 (Herpes B virus);
Chikungunya virus;
Chlamydophila psittaci;
Clostridium perfingens epsilon toxin;
Coccidioides immitis;
Coccidoides psadiasii;
Reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments (Reconstructed 1918 influenza virus);
Conotoxins;
Cowpox;
Coxiella burnetii;
Crimean-Congo haemorrhagic fever virus;
Cryptosporidium parvum;
Dengue virus;
Diacetoxyscirpenol;
Eastern Equine Encephalitis virus;
Ebola virus;
Escherichia coli 0157: H7;
Far Eastern tick-borne encephalitis;
Flexal;
Fransicella tularensis;
Guana rito;
Hendra virus;
Influenza virus (highly pathogenic): H5N1, H7N1, H7N3, H10N8, H9N2, H7N7, H5N6;
Japanese encephalitis virus;
Junin;
Kyasanur Forest disease;
Lassa fever virus;
Machupo;
Marburg virus;
Menangele virus;
MERS corona virus (Middle East respiratory syndrome);
Monkeypox virus;
Nipah virus;
Omsk Haemorrhagic Fever;
Ricin;
Rickettsia prowazekii;
Rickettsia rickettsii;
Rift Valley fever virus;
Russian Spring and Summer encephalitis;
Sabia;
SARS corona virus (Severe acute respiratory syndrome);
SARS Corona virus 2 (Severe acute respiratory syndrome coronavirus; SARS-CoV-2),
also known as Novel coronavirus 2019–(nCov-2019);
Saxitoxin;
Shiga-like ribosome inactivating proteins;
Shigatoxin;
Staphylococcal enterotoxins;
T-2 toxin Venezuelan Equine Encephalitis virus;
Tetrodotoxin;
Variola major virus (Smallpox);
Variola minor virus (Alastrim);
Venezuelan equine encephalitis;
Vibrio cholera (O1, O139);
Western Equine Encephalitis;
Yellow fever virus;
Yersina pestis;
Zika virus;
except for preparations registered in the pharmaceutical register maintained pursuant to section 47a of the Pharmacists Ordinance [New Version], 5741-1981.
Ehud Olmert Yaakov Ben Yizri
Prime Minister Minister of Health
Shimon Peres Dalia Itzik
President of the State Speaker of the Knesset
Read the entire law on one page — continuous text, no page breaks, plus formal citations.